DE602005024955D1 - Faktor ixa zur behandlung von blutungsstörungen - Google Patents

Faktor ixa zur behandlung von blutungsstörungen

Info

Publication number
DE602005024955D1
DE602005024955D1 DE602005024955T DE602005024955T DE602005024955D1 DE 602005024955 D1 DE602005024955 D1 DE 602005024955D1 DE 602005024955 T DE602005024955 T DE 602005024955T DE 602005024955 T DE602005024955 T DE 602005024955T DE 602005024955 D1 DE602005024955 D1 DE 602005024955D1
Authority
DE
Germany
Prior art keywords
factor ixa
factor
bleeding
treatment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005024955T
Other languages
English (en)
Inventor
Shane Donovan
Donald A Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of DE602005024955D1 publication Critical patent/DE602005024955D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
DE602005024955T 2004-03-19 2005-02-28 Faktor ixa zur behandlung von blutungsstörungen Active DE602005024955D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55472604P 2004-03-19 2004-03-19
PCT/US2005/006527 WO2005094873A1 (en) 2004-03-19 2005-02-28 Factor ixa for the treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
DE602005024955D1 true DE602005024955D1 (de) 2011-01-05

Family

ID=34961495

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005024955T Active DE602005024955D1 (de) 2004-03-19 2005-02-28 Faktor ixa zur behandlung von blutungsstörungen

Country Status (10)

Country Link
US (2) US7425539B2 (de)
EP (1) EP1755652B1 (de)
JP (2) JP5037331B2 (de)
AT (1) ATE489105T1 (de)
AU (1) AU2005228945B2 (de)
CA (1) CA2557061C (de)
DE (1) DE602005024955D1 (de)
ES (1) ES2357132T3 (de)
HK (1) HK1102366A1 (de)
WO (1) WO2005094873A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425539B2 (en) * 2004-03-19 2008-09-16 Baxter International Inc. Factor IXa for the treatment of bleeding disorders
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553940B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
MY167814A (en) 2012-04-19 2018-09-26 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
CA2891393A1 (en) 2012-11-20 2014-05-30 Opko Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
FR3032621A1 (fr) 2015-02-13 2016-08-19 Lab Francais Du Fractionnement Colle biologique et son utilisation comme medicament
JP6698102B2 (ja) * 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法
CN108289851B (zh) 2015-06-19 2021-06-01 Opko生物科学有限公司 长效凝固因子及其产生方法
US20180369346A1 (en) * 2016-01-07 2018-12-27 Eio Biomedical Ltd. Methods, compositions and kits for reducing tissue adhesions
CN107758662B (zh) * 2017-10-10 2019-08-20 中国石油大学(华东) 一种磷酸法活性炭活化时间的确定方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560475A (en) * 1969-06-19 1971-02-02 Baxter Laboratories Inc Prothrombin complex prepared by precipitation with polyethylene glycol
US4286056A (en) 1980-01-28 1981-08-25 Baxter Travenol Laboratories, Inc. Method for making therapeutic enzyme compositions
US4357321A (en) * 1980-01-28 1982-11-02 Baxter Travenol Laboratories, Inc. Method and composition for treating clotting factor inhibitors
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
AU5864086A (en) 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
DE3877529T2 (de) 1987-10-23 1996-11-07 Centre Regional De Transfusion Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
US20040072757A1 (en) 1990-09-04 2004-04-15 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
DE19506633A1 (de) 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
CN100553678C (zh) * 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
EP1048736A1 (de) 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung DNA-Konstrukt für die Gewebespezifischen Expression eines Blutkoagulationsfaktors
US6441144B1 (en) * 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US6624289B1 (en) * 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001047510A2 (en) * 1999-12-29 2001-07-05 Glaxo Group Limited Methods and compositions related to modulators of annexin and cartilage homeostasis
US7572619B2 (en) 2000-03-22 2009-08-11 Octagene Gmbh Recombinant blood clotting factors
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US7015193B2 (en) 2001-04-20 2006-03-21 University Of Vermont Compositions and methods to control bleeding
CA2465004A1 (en) 2003-05-19 2004-11-19 National Institute For Biological Standards And Control Composition
US7425539B2 (en) * 2004-03-19 2008-09-16 Baxter International Inc. Factor IXa for the treatment of bleeding disorders

Also Published As

Publication number Publication date
HK1102366A1 (en) 2007-11-16
CA2557061A1 (en) 2005-10-13
ATE489105T1 (de) 2010-12-15
ES2357132T3 (es) 2011-04-19
EP1755652A1 (de) 2007-02-28
WO2005094873A1 (en) 2005-10-13
US20050209149A1 (en) 2005-09-22
US7425539B2 (en) 2008-09-16
JP2012126743A (ja) 2012-07-05
AU2005228945A1 (en) 2005-10-13
CA2557061C (en) 2013-08-20
JP2007529518A (ja) 2007-10-25
JP5037331B2 (ja) 2012-09-26
EP1755652B1 (de) 2010-11-24
US7767647B2 (en) 2010-08-03
US20090069543A1 (en) 2009-03-12
AU2005228945B2 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
ATE489105T1 (de) Faktor ixa zur behandlung von blutungsstörungen
EA200401525A1 (ru) Способы лечения гепатита (варианты )
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE60204322D1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
TW200612892A (en) Novel compounds
CY1112253T1 (el) Ενωσεις διαμινοτριαζολιου χρησιμες ως αναστολεις κινασης πρωτεϊνης
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
DE602005026276D1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
DE602004018788D1 (de) Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE399165T1 (de) Chinolinverbindungen und deren verwendungen
IL177286A0 (en) Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing same
ATE549023T1 (de) Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
UA85676C2 (en) Carbonyl compounds
ATE525073T1 (de) Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
ATE397924T1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
DE502007002353D1 (de) Verfahren zur herstellung von cyclischen ketonen
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.